NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dowell, J., Gettinger, S., Gubens, M. A., Hegde, A., Hennon, M., Lackner, R. P., Lanuti, M., Leal, T. A., Lin, J., Loo, B. W., Lovly, C. M., Martins, R. G., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Patel, S. P., Riely, G. J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Yanagawa, J., Yang, S. C., Gregory, K. M., Hughes, M. 2021; 19 (3): 254–66

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

View details for DOI 10.6004/jnccn.2021.0013

View details for PubMedID 33668021